Please note that this content was created in 2018. In the time since this material was posted, there may have been additional developments, advancements, and/or more current publications in this field.
AMP Education is constantly updating our educational offerings, and will remove or replace content that is no longer accurate. Please be sure to use the search function to find related or updated material available in our catalogue at educate.amp.org. The Training and Education Committee works with AMP Education Programs to bring you the most up-to-date and cutting-edge information on molecular pathology research, applications, and training.
This is a recording of a session from the AMP 2018 Annual Meeting & Expo. Purchase the entire AMP Annual Meeting & Expo 2018 Recordings for a significant discount!
This session will describe inherited mutations that confer an increased risk for the development of hematopoietic malignancies. We will cover the World Health Organization's provisional category for germline predisposition to myeloid malignancies as well as what is known regarding predisposition to lymphoid malignancies. We will also discuss the detection of germline mutations from next-generation sequencing panels used in prognostication of acute leukemias. Acquired mutations in genes that code for core components of the spliceosome are common in several hematopoietic malignancies. This session will also review what is known about altered RNA splicing and abnormal hematopoiesis induced by spliceosome gene mutations. In addition, we will discuss novel therapeutic strategies to target spliceosome mutant cells in patients with myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML).
Spliceosome Gene Mutations in MDS
Matthew Walter, MD, Washington University, St. Louis, MO, USA
Inherited Hematopoietic Malignancies
Lucy A. Godley, MD, PhD, The University of Chicago, Chicago, IL, USA
Objectives:
- Outline the current WHO classification for germline predisposition to myeloid malignancies.
- Describe ways in which molecular profiling can be used to detect a germline syndrome.
- Discuss ongoing variant curation by the ClinGen Myeloid Malignancy Committee.
- Define the spliceosome genes that are commonly mutated in MDS and AML.
- Summarize the types of RNA splicing alterations induced by spliceosome gene mutations.
- Recognize novel treatment approaches for patients with spliceosome gene mutations.
Duration: 1.50 hr
Recording Date: November 1, 2018
Last day to purchase: December 31, 2021
There are no CME/CMLE or SAMs credits available.Note: Join the AMP Family for discounted access to the most current educational resources!
All sales are final. No refunds will be issued.
No digital files may be reproduced or transmitted in any form, by any means, electronic or mechanical. By purchasing a product, you agree to not share any of the course materials, including videos, downloadable slide presentations, outlines, manuscripts, etc. without explicit and written permission from AMP.
